CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B

Mi Young Jeon, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim

Clin Mol Hepatol. 2021;27(2):295-304. Published online 2020 December 3 DOI: https://doi.org/10.3350/cmh.2020.0216

Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B

Mi Young Jeon, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim

Clinical and Molecular Hepatology. 2021;27(2):295-304

Link1

Link2 Link3

Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact

Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, Vincent Wai-Sun Wong

Clinical and Molecular Hepatology. 2021;27(2):273-277

Link1

Link2 Link3

Are the Patients in the Immune Tolerant Phase of Chronic Hepatitis B far from Hepatocellular Carcinoma or Death?

Nae-Yun Heo

The Korean Journal of Gastroenterology. 2019;74(1):66

Link1 Link2 Link3

Significant heterogeneity in long-term risks of cirrhosis or hepatocellular carcinoma among a national cohort of U.S. veterans with non-cirrhotic, treatment naïve chronic hepatitis B in the immune tolerant phase

Zeyuan Yang, Ramsey C. Cheung, Robert Wong

Journal of Hepatology. 2023;78:S1107

Link1 Link2

Letter: risk of hepatocellular carcinoma in immune‐tolerant phase of chronic hepatitis B

Mayur Gattani, Meghraj Ingle, Shamshersingh Chauhan, Saiprasad Lad

Alimentary Pharmacology & Therapeutics. 2020;52(5):911-912

Link1 Link2

Letter: risk of hepatocellular carcinoma in immune‐tolerant phase of chronic hepatitis B—authors’ reply

Han Ah Lee, Seung Up Kim

Alimentary Pharmacology & Therapeutics. 2020;52(5):913-914

Link1 Link2

Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B

Hye Won Lee, Young Eun Chon, Beom Kyung Kim, Terry Cheuk-Fung Yip, Yee-Kit Tse, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Henry Lik-Yuen Chan, Sang Hoon Ahn

European Journal of Internal Medicine. 2021;84:68-73

Link1 Link2

Cost-effectiveness of suppressing hepatitis B virus DNA in immune tolerant patients to prevent hepatocellular carcinoma and cirrhosis

A. D. ENRIQUEZ, M. S. CAMPBELL, K. R. REDDY

Alimentary Pharmacology & Therapeutics. 2007;26(3):383-391

Link1 Link2

Comparable risk of hepatocellular carcinoma between immune-tolerant and active phase in hepatitis B e antigen-positive patients

Han Ah Lee, Seung Up Kim, Yeon Seok Seo, Chai Hong Rim

Journal of Hepatology. 2022;77:S283-S284

Link1 Link2

Immune Tolerant Chronic Hepatitis B: The Unrecognized Risks

Patrick Kennedy, Samuel Litwin, Grace Dolman, Antonio Bertoletti, William Mason

Viruses. 2017;9(5):96

Link1

This metadata service is kindly provided by CrossRef from May 29, 2014. Clin Mol Hepatol has participated in CrossRef Text and Data Mining service since March 1, 2015.